Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.

Data were presented by a Principal Investigator for Provectus's Phase 2 melanoma study, Professor Merrick Ross, M.D., of the MD Anderson Cancer Center in Houston, Texas. Dr. Ross delivered a presentation entitled "Intralesional therapy: local/regional control and implications for systemic response." He provided a comprehensive review of intralesional therapies, starting with BCG (Bacillus Calmette-Guérin) and IL-2 (Interleukin-2) as antecedents to several promising modern intralesional therapies, including PV-10, that are currently undergoing advanced clinical testing. His presentation focused on the role of intralesional therapies for control of both local disease and their possible effect on systemic disease, such as that shown in Phase 2 testing of PV-10. Dr. Ross also confirmed that nonclinical studies, which are designed to characterize the immunologic response to PV-10 chemoablation, are being conducted by researchers at the Moffitt Cancer Center in Tampa, Florida.

Dr. Craig Dees, PhD, CEO of Provectus said, "As we prepare for a multi-center, global Phase 3 trial for PV-10 for metastatic melanoma, we are excited about Dr. Ross' presentation of the Phase 2 results at this major international meeting. This and other recent presentations reinforce the role that PV-10 can play in the management of melanoma, particularly in the large population of patients with locoregional metastatic disease. With nearly 170 melanoma patients having received PV-10 since 2005, we take further encouragement from the positive reception of PV-10 in this and recent diverse venues as evidence that the investigational therapy ultimately will be well received by the melanoma community."